City
Epaper

Remedium Lifecare Delivers Strong Q2 Results with Profit Nearly Doubling to INR 3862.34 Lakh

By ANI | Updated: November 17, 2025 14:40 IST

PNNMumbai (Maharashtra) [India], November 17: Remedium Lifecare Limited announced its financial results for the quarter and half-year ended ...

Open in App

PNN

Mumbai (Maharashtra) [India], November 17: Remedium Lifecare Limited announced its financial results for the quarter and half-year ended September 30, 2025.

During the quarter ended September 30, 2025, the consolidated financial results reflect strong operational momentum. Consolidated revenue from operations stood at ₹11,105.82 lakh, with total income reaching ₹11,431.25 lakh. The quarter recorded a consolidated profit before tax 0f ₹1,043.69 lakh and a profit after tax of ₹862.34 lakh, with earnings per share of ₹0.10 which has doubled compared to Q1 FY26.

- PAT Sep-25 up by 85.49% at 2.862.34 lakh vs Jun-25 ₹.464.88 lakh

- EBITDA Sep-25 up by 82.70% at ₹.1043.69 lakh vs Jun-25 ₹.571.23 Lacs

- PAT Half year FY26 is at 1327 lakhs vs PAT 12 months FY24-25 at 213 lakhs.

For the half year ended September 30, 2025, consolidated revenue from operations was ₹22,442.39 lakh and total income stood at ₹23,115.60 lakh. Profit before tax for the half year was ₹1,614.92 lakh, while profit after tax stood at ₹1,327.22 lakh, translating to an earnings per share of ₹0.15. Consolidated total assets as on September 30, 2025 amounted to ₹1,62,318.10 lakh.

Commenting on the financial performance, Mr. Adarsh Munjal, Whole-Time Director, said: "The second quarter results reflect our continued commitment to operational discipline and the business expansion. Our consolidated performance demonstrates the strength of our portfolio and our ability to scale efficiently. We are confident that this momentum will continue through remainder of the financial year as we focus on improving profitability, strengthening our asset position, and driving sustainable growth for all stakeholders."

Remedium Lifecare has recently reinforced its leadership structure with the appointment of Mr. Rambhajan Vishwakarma and Mr. Vignesh Laxman Gawde on the Board, signifying a renewed focus on governance, global expansion and scaling of CDMO capabilities.

In parallel, the Company's strategy of leveraging its global-subsidiary footprint (including Singapore incorporation in September 2024) and expanding CDMO service offerings underscores its ambition to strengthen and monetise its specialty pharma and chemicals business.

About Remedium Lifecare Ltd.:

Founded in 1988, Remedium Lifecare is a BSE-listed pharmaceutical and specialty chemicals company engaged in trading and distribution of raw materials for the pharmaceutical industry. With a strong emphasis on quality, compliance, R&D, and global market expansion, the Company plays a strategic role in India's pharmaceutical ecosystem.

(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN.will not be responsible in any way for the content of the same.)

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

BusinessDPA Kandla Chairman highlights sustainability, shipbuilding potential at Vibrant Gujarat Conference

NationalArmy successfully foils multiple drone incursions by Pakistan along international border in J&K

EntertainmentBigg Boss Marathi 6: Raqesh Bapat Enters the House, Chooses ‘Door of Hard Work’ Over Shortcut

EntertainmentJudd Apatow reveals he "quietly boycotted" Golden Globes for 10 years afterosing to 'The Martian'

NationalAAP Sarpanch Murder Case: Punjab Police Nab 7 Accused After Multi-State Chase, DGP Confirms

Business Realted Stories

BusinessUnsecure lending by banks surge to Rs 46.9 lakh crore, raising risk sensitivity: SBI report

BusinessDigital Innovation at AU Small Finance Bank Reshapes Savings Accounts and Interest Rate Growth

BusinessMeitY conducts routine stakeholder consultations on mobile security standards

BusinessBCCL IPO 2 Day: Check Subscription Status and GMP on the Second Day of Bidding

BusinessRelaxation for Chinese firms unlikely to disrupt domestic power equipment sector: Report